Working with cancer whole genomes sequenced over a period of many years in different 32 sequencing centres requires a validated framework to compare the quality of these 33 sequences. The Pan-Cancer Analysis of Whole Genomes (PCAWG) of the International 34
Introduction 46
Combining whole genome sequencing data from individual projects has many 47 advantages: increased statistical power, the ability to extend hypotheses across several 48 projects and the possibility of asking biological questions covering a wider range of 49 phenomena. However when the genome sequencing data comes from different centres, 50 was sequenced at different times and under different protocols, great care must be taken 51 to ensure that the sequencing data is of comparable quality, to avoid drawing false 52 conclusions. The Pan-Cancer Analysis of Whole Genomes (PCAWG) project provided us 53 with a great opportunity to assemble, test and finalise which quality control measures are 54 important for comparing the quality of whole genome, cancer sequences. 55
The PCAWG project assembled a cohort of 48 projects encompassed in the International 56
Cancer Genome Consortium (ICGC) 1 and The Cancer Genome Atlas (TCGA) 2 of which 57 we analysed 2959 cancer genomes (normal-tumour genome pairs) from 2830 donors. The 58 size of the dataset and the diversity of the samples, representing many different cancers 59 from varied populations, allow the exploration of many fundamental questions of cancer. 60
Although there were inclusion criteria based on the sequencing platform (Illumina) and 61 minimum sequencing depth, there was a need to ascertain the quality of the sequencing 62 data and how they compared to each other. There were 17 different sequencing centres 63 involved and the sequencing was performed in over a five year time-span (2009-2014) (a 64 time period of during which the sequencing methodology was still evolving rapidly), so 65 to be able to perform analysis across the whole data set, it was necessary that the quality 66 of the sequencing was carefully assessed. 67
There are advantages in developing a comprehensive set of quality measures. We will be 68 able to exclude samples of low quality. This will save running downstream analyses, 69 saving computational and the researchers' time. For researchers in PCAWG studying 70 driver mutations, we can provide a sanity check. If the driver mutation is only found in 71 low quality samples, it may not be a good candidate, compared to if it is supported by 72 high quality samples. As PCAWG will release the data for community to use, our quality 73 measures will provide a guide to the quality of the whole genome sequences within. For 74 researchers who wish to assess the quality of their whole genome cancer sequences, we 75 will also be releasing our methods, in a Docker Container for easy implementation. 76
77
To develop a framework needed to determine the quality of samples, we use the methods 78 employed by the sequencing centres involved in PCAWG as well as results in the 79 literature. TCGA marker papers (see references [3] [4] [5] for examples from 2014-16) all include 80 quality control (QC) measures such as depth of coverage, batch effects and contamination 81 levels, as calculated as part of the Firehose analysis infrastructure. Likewise a recent 82 ICGC paper 6 with samples sequenced from three different centres relied on similar QC 83 measures computed by the Picard toolkit. Lu et al. 7 , carried out meta-analysis of exome 84 data available from the TCGA for 12 cancer types which is similar, but not identical in 85 scope, to the data set examined here. Their inclusion criteria were based on coverage 86 depth and percentage of exome coverage for both the normal and tumour samples. Other 87 cancer studies have also pointed to the importance of the percentage of the genome 88 covered 8,9 as well as error rates for each of the paired reads 10 as QC measures. The scale 89 and diversity of the PCAWG project provides a useful testing ground for QC measures, 90 both for selection of the measures and the thresholds to use in grading the sequences. 91
Here we present the results of the work by sequencing centres and research groups 92 involved in PCAWG to define important quality control measures, and how best to 93 combine the results from these measures. Based on the PCAWG data we selected 94 measures covering five important features to assess the quality of cancer genome 95 sequences: mean coverage, evenness of coverage, somatic mutation calling coverage, 96 paired reads mapping to different chromosomes and the ratio of difference in edits 97 between paired reads, an edit being a base in the read which is different to the reference 98 genome. These measurements we computed for both the normal and tumour samples. To 99 summarise the five QC measures, we established a star rating system to cover the range 100 of the highest quality cancer genomes, passing the thresholds set for each measurement, 101 to those that had many sequencing quality issues. 102
Results 103
All our analysis is based on the aligned sequences from the PCAWG core pipeline 11 . 104
Within the aligned sequences we did not use duplicate reads, reads with a mapping 105 quality of zero and ignored supplementary alignments. The first three quality control 106 measures; mean coverage, evenness of coverage and somatic mutation calling coverage; 107 are linked to different aspects of the coverage of the genomic sequence. The other two 108 measures indicate discrepancies between the paired reads: mapping to different 109 chromosomes and the ratio of edits between the paired reads compared to the reference 110 genome. Finally we summarise these five measures into a star rating, for easy comparison 111 of each of the sample pair's quality. 112
Mean Coverage
When deciding on what depth to sequence cancer genomes to, a trade 113 off has to be made between the advantages of sequencing deep to the cost of sequencing. 114
The deeper the cancer genome is sequenced the greater the confidence in calling somatic 115 events (see Tyler et al. 12 for a comparison of somatic mutation calling at depths up to 116 300X). A precondition for the inclusion of a patient in the PCAWG study was the 117 availability of a whole genome sequence of the normal and tumour with 25X coverage or 118 greater. We found that a number of the submitters calculated coverage differently. For 119 standardization the mean number of reads covering each position in the genome was 120 calculated, after low quality and duplicate reads were excluded so to not inflate the 121 number of reads (see Supplementary Methods for exact methods used). As shown in 122
Supplementary Figure S1 , most commonly the normal samples were sequenced to around 123 30X, while there was a bimodal distribution for the tumour samples with maxima at 38X 124 and 60X. To provide a meaningful guide to the quality of the genomes in PCAWG, we 125 therefore set the thresholds for the mean coverage, after aligning, to 25X for normal 126 samples and 30X for tumour samples. This resulted in 0.4% normal and 2.2% tumour 127 samples not reaching these minimum criteria (see Supplementary Figure S1 ). 128
Evenness of Coverage To confidently identify germline variants and somatic mutations 129
requires an even coverage across the target area 13 , in this case the entire genome. Two 130 different methods, in use by the sequencing centres involved for whole genomes, were 131 chosen. One measure is to calculate the ratio of the median coverage over the mean Figure S2 ). For MoM coverage ratio (and for FWHM described below), there is a greater 139 range of values for the tumour samples than normal samples, potentially due to 140 biologically reasons valid for tumours, e.g. large deletions could lead to a more unevenly 141 covered sample. If the normal sample is unevenly covered, it is more likely due to a 142 sequencing artefact. Hence, we are more stringent for the normal than the tumour 143
samples. 144
The second measure of evenness looks at the variation of the normalised coverage in ten 145 kilobase (kb) genomic windows, after correction for GC-dependent coverage bias using 146 the somatic CNV calling algorithm ACEseq 14 (Figure 2) . The main cloud, which 147 corresponds to the main copy number state of the sample, is determined (as shown by the 148 red dots in Figure 2 ). The remaining coverage variation is measured as full width at half 149 maximum (FWHM) of the main cloud. This measure is insensitive to copy number 150 aberrations and GC-dependent coverage bias. To determine the thresholds, 1000 WGS 151 samples from different tumour types were used. We chose the pruning values based on 152 clustering of these samples and subsequent visual inspection of the "best" samples that 153 exceeded the threshold to see whether they are valid. Using these results the thresholds 154 chosen are 0.205 for the normal and the more lenient 0.34 for the tumour, above which 155 the sample would be regarded as having an uneven coverage (see Supplementary Figure  156 S3). 157
The two evenness measures tend to identify different samples as having uneven coverage 158 (see Figure 3 ). Spearman's correlation coefficient for the two measures suggests that 159 these measures are not correlated for the normal (ρ = 0.24) and tumour (ρ = −0.06) 160 samples. FWHM is insensitive to GC bias, as the CNV caller corrects for this while MoM 161 identifies other evenness outliers. 162
A sample needs to be in the respective ranges of the MoM and FWHM for the normal and 163 the tumour to pass the evenness quality measure, of which 6.28% and 5.81% respectively 164 of the samples were not. Figure S4) . 180
Paired reads mapping to different chromosomes The two reads from a read pair 181 should represent the ends of a contiguous DNA sequence that depending on the insert 182 size should be a given distance apart (for PCAWG between 200 and 1,000 bases). Paired 183 reads mapping to different chromosomes can be due to a rearrangement. However an 184 excess of reads mapping to different chromosomes points to a technical artefact. So 185 deciding a threshold based on percentage of paired reads mapping to different 186 chromosomes, we should not penalise sequences with biological causes of the paired 187 reads mapping to different chromosomes (such as chromothripsis 17 , or more generally, 188 interchromosomal rearrangements). We set the threshold to 3%, which even samples with 189 confirmed high levels of rearrangements and chromothripsis do not exceed (which in our 190 experience, do not have more than 1% of paired reads mapping to different 191 chromosomes). Of the normal sequences 14.5% exceed the threshold, as do 13.0% 192 tumour sequences (see Supplementary Figure S5 ). Interestingly there are more normal 193 samples failing this measure, which cannot be explained by biological processes. A 194 possible explanation may be that for lower quality samples in preparing libraries with 195 PCR amplification, this amplification step causes an increase in two fragments of DNA 196 from different parts of the genome being fused together, as has previously been noted 18 . 197 Consequently, this translates to an increase in percentage of paired reads mapping to 198 different chromosomes. 199
Ratio of difference in edits between paired reads Damage in sequencing runs has been 200
linked to a global imbalance in edits (where the base in read is different compared to the 201 reference) between read 1 and read 2 in paired end sequencing 19 . Therefore the ratio of 202 the sum of edits between paired reads for a well-sequenced sample should be close to 203 one. We adjudged samples with a two-fold ratio of edits between the paired reads, or 204 greater, as having something gone wrong in the sequencing cycle resulting in lower data 205 quality. Based on this threshold 4.66% and 4.49% normal and tumour samples failed 206
respectively. 207
Summary The five quality measures were selected to provide minimal redundancy in 208 flagging quality issues in normal/tumour paired genome sequences -that each measure 209 reflects a facet of sequencing quality that other measure does not. The best way to 210 summarise these comparisons between the different measures is with a Venn diagram 211 ( Figure 4) . There is some overlap between certain measures, for example 75 sample pairs 212 are penalised by both having a high percentage paired reads mapping to different 213 chromosomes and uneven coverage. However a much higher number of samples 214 penalised by one of these measures and not the other. Having defined these five, non-215 redundant QC measures our next step was to summarise them, to give an overall score for 216 quality for the other researchers in PCAWG to use. 217
Star rating system 218
We used the five quality measures to construct a star rating for each cancer genome 219 at the different projects (see Figure 5 ), a more nuanced picture is available. The quality 229
does not seem to be biased by tissue type (see Supplementary Figure S7 ) based on 230 detailed molecular subtypes of the tumours in PCAWG 20 , the difference seems to be 231 more at the project level. Unfortunately, there is only limited project metadata on when 232 and which protocol was used to sequence the samples. Figure S8 ). We found similar results for a subset of 348 samples sequenced at the Broad 241
Institute (see supplementary Figure S9 ), which had metadata recorded in CGHub 21 about 242 the time and instruments used to sequence. We hypothesise that this will be true for other 243 projects as well. 244
Having calculated the star rating for the sequences, it was interesting to see how our QC 245 measures relate to the calling of somatic single nucleotide variants (SNVs) 11 , somatic 246 insertion and deletions (indels) 11 and somatic structural variants (SVs) 22 in PCAWG. An 247 advantage of using these PCAWG datasets is that four callers were used for each. 248
Looking at the proportion of calls, which all four callers supported, gives us a good idea 249 how the quality of sequencing influences the identification of unambiguous somatic 250 mutations. While the proportion of calls supporting the four callers varies greatly by 251 sample, we find that the samples with four stars or greater tended to have higher 252 proportions than samples with less than four stars for SNVs, indels and SVs (with p-253 values of ~10 -5 , ~10 -5 , ~10 -18 respectively, using the Mann-Whitney-U test, also see 254 Figure 6 ). 255
Taking this analysis further we used linear regression models, to further analyse the 256 relation between the proportion of calls supported by four callers and the actual QC 257 measures (see Supplementary Tables S1-S3 ). The results show that, significantly, an 258 increasing percentage of paired reads mapping to different chromosomes in tumour 259 samples, has a negative effect on the proportion of calls supported by four callers for 260
SNVs, indels and SVs. More specifically, for SNVs an increasing mean coverage in 261 tumours has a significant positive effect on the proportion of calls supported by four 262 callers. While in indels there is a significant effect negative effect on the proportion of 263 calls supported by four calls by increasing unevenness (as measured by FWHM) in 264 tumours. As in indels, the unevenness effect is also true in SVs as well as significant 265 negative effects by increasing percentage of paired reads mapping to different 266 chromosomes in normal samples and ratio of difference in edits between paired reads in 267 tumour samples. 268
The results from this analysis suggest the quality of sequencing as measured by star 269 rating does have a measurable effect the downstream analyses. However the QC 270 measures which make up the star rating effect the different downstream analyses in 271 different ways. As our QC measures reflect different aspects of sequencing quality, they 272 also have varying levels of importance in using these sequences in the downstream 273 analyses of calling SNVs, indels and SVs. 274
Discussion 275
The established star rating system allows grading the normal and tumour sample 276 sequences by quality in absence of information on how sequencing was carried out, what 277 protocols were used and what problems may have occurred during the sequencing 278 process. The system is not designed to be all encompassing, instead using a small amount 279 of computational resources and time (compared to the actual aligning of the sequences), 280
we get a good snapshot of the quality of the normal-tumour sample pair sequences on 281 which to call somatic mutations. Likewise having graded the cancer genomes with our 282 five-star system, we do not intend researchers to necessarily exclude the lower ranked 283 cancer genomes, just to be wary of any conclusions based solely on the lower scoring 284
genomes. 285
With our star rating system, we sent several samples to the exclusion list due to their poor 286 performance in one of the QC measures. Due to the timing, this did not prevent the 287 downstream analyses being performed. Though anecdotally it would have saved 55 days 288 computational runtime for our one star sample. For all samples that remained, the QC star 289 rating was embedded in the header of the variant call format files for use of the 290 researchers within PCAWG, and when the data is released, to all researchers. 291
For those projects in PCAWG, which we had metadata, we found that sequencing quality 292 has definitely improved over the time period 2009-2014 in which the samples sequenced. 293
Our results for the CLLE-ES project suggest that in part a protocol change to PCR-free 294 methods improved sequencing, as in line with best practices from a recent benchmarking 295 exercise. 12 296
Another advantage of our quality control is the link to the downstream analyses. In 297 aggregate, the higher the quality of the sequences, had a higher proportion of the 298 consensus somatic SNVs, indels, SVs called. These results suggest overall that higher 299 quality sequence will identify the true positive somatic mutations with higher probability. 300
Our data would suggest that when pre-amplification of DNA will be needed for WGS, 301 e.g. DNA isolated from formalin fixed, paraffin embedded tissue, the star rating system 302 will be helpful when the variants and mutations are interpreted. 303
We believe that our method can be adapted for similar projects that look to use whole 304 genome sequences from a variety of sources. The thresholds we used based on our 305 experience and applied to this dataset of 2959 cancer genomes can also be used as guide 306 to quality of sequences. It is worth noting that they represent a trade-off of being severe 307 enough to penalise poor quality while not discriminating against samples with valid 308 biological causes. We also would recommend using our methods to ascertain the quality 309 before downstream analyses by other groups. To enable others to use our approach, there 310 is a Docker Container, which can be accessed at https://github.com/eilslabs/PanCanQC. 311
We provide a framework for quality assessment, which opens the door to do large-scale 312 meta-analysis in a more robust framework. sample. As shown in the plot the tumour samples have a greater spread of values than the 398 normal, we hypothesize this is to be expected as tumours are more likely to have deletions 399 and structural rearrangements, which will lead to less evenly covered sequence. The 400
whiskers on each of the boxplots (0.99-1.06 for the normal and 0.92-1.09 for the tumour) 401
were taken as thresholds for this measure. than four stars. This is significant using the Mann-Whitney U test, with p-value ~ 10 -8 . 447
